Due Diligence in AI: Thinking like your biggest critic
Reel Shorts | Labor & Employment: Navigating AI Compliance Risks in Recruiting
AI Discrimination and Emerging Best Practices – Part 1 — The Good Bot Podcast
Due Diligence in AI: 3 things you need to survive AI scrutiny
How can founders navigate the explosion of state AI regulations?
Using Innovative Technology to Advance Trial Strategies | Episode 70
Dan Rudoy Examines the Impact of AI on IP Strategy
The Burr Broadcast: AI in the Workplace
Exploring the CFPB's Stance on AI in Financial Services — The Consumer Finance Podcast
Joe Green & Monica Rodriguez Kuniyoshi on Integrating Generative AI with Your Experts: Passle CMO Series Live Podcast
Preventative Medicine: Health Care AI Privacy and Cybersecurity – Part 2 — The Good Bot Podcast
When AI Meets PI: Assessing and Governing AI from a Privacy Perspective
Seeing into the Future: Moving Beyond AI to Visual Intelligence with Oculi CEO Charbel Rizk
A Brief Overview of Colorado’s Recently Enacted AI Law
Employment Law Now VIII-149 - Part 2 of 2: The Final Interview With EEOC Commissioner Keith Sonderling
Employment Law Now VIII-148- Part 1 of 2: The Final Interview With EEOC Commissioner Keith Sonderling
Law School Toolbox Podcast Episode 467: Surviving Migration in the Age of Technology (w/Petra Molnar)
(Podcast) The Briefing: Deep Dive into the NO FAKES Act
The Briefing: Deep Dive into the NO FAKES Act
AI in the Operating Room: Liability Issues for Device Makers — The Good Bot Podcast
n March 15, the U.S. Food and Drug Administration (FDA) published a paper titled “Artificial Intelligence and Medical Products: How CBER, CDER, CDRH, and OCP are Working Together.” This paper describes the FDA’s strategy for...more
On March 15, 2024, four of the US Food and Drug Administration’s (FDA) medical products centers released a joint paper, titled “Artificial Intelligence & Medical Products: How CBER, CDER, CDRH, and OCP are Working Together,”...more
The Food and Drug Administration’s (FDA’s) Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), Center for Devices and Radiological Health (CDRH), and Office of Combination...more
On March 15, 2024, FDA published a white paper titled “Artificial Intelligence & Medical Products: How CBER, CDER, CDRH, and OCP are Working Together” (the AI White Paper) on the use of artificial intelligence (AI) across the...more
The year 2023 was a busy one for regulatory, compliance, and enforcement developments in the healthcare and life sciences industries, and 2024 promises to be even busier. We tapped MoFo’s Life Sciences + Healthcare Compliance...more
In recent years, the digitalization of the healthcare industry has been accelerated to meet demands for smarter devices and robotics, wearable technology, AI-based data analysis, and enhanced platforms and simulations, among...more
On January 12, 2021, the U.S. Food and Drug Administration (FDA) released the Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan (Action Plan). The Action Plan expresses...more
On September 22, 2020, the U.S. Food and Drug Administration (FDA) announced the establishment of the Digital Health Center of Excellence (DHCE) within FDA’s Center for Devices and Radiological Health (CDRH). Bakul Patel will...more